These 4 Habits Could Help You Avoid Cognitive Decline, New Study Says
A new study suggests exercise, diet and regular healthcare check-ups may lower dementia risk.
That includes physical exercise—ideally six times per week—and mental exercises to keep you sharp.
Following the MIND diet, a combination of the Mediterranean and DASH diets, may also support better brain health.Alzheimer's disease (AD) and related dementias are significant public health challenges for many reasons. More people are being affected by dementia, and the condition can bring heavy emotional, social and financial burdens. And as much as you or a loved one may want to lower your dementia risk, it can be hard to figure out where to start.
Memory decline in older adults often has multiple causes, so effective treatments ideally tackle several targets at once. While new medications that target amyloid (a group of proteins linked to Alzheimer's) show promise in slowing the disease in its early stages, they don't address other common problems like blood vessel damage in the brain, which can also contribute to memory loss. This highlights the need for better, more comprehensive treatments.
Non-drug approaches, like improving lifestyle factors, offer a safe, affordable, and accessible way to reduce dementia risk. A groundbreaking study in Finland (called the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability, or FINGER) showed that combining certain healthy lifestyle changes improved memory and thinking in older adults at risk for dementia.
To determine if the positive results from the FINGER study in Finland could also apply to a larger and more diverse group of people in the United States who are at risk for dementia, researchers studied this method's impact on brain health and thinking abilities, and the results were published in JAMA. This study was called the U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk, or U.S. POINTER.
How Was This Study Conducted?
Researchers recruited subjects for this study by using electronic health records and by working with local community organizations to reach people directly. The goal was to include older adults (ages 60 to 79) who didn't have memory problems but were at higher risk of developing dementia.
To qualify, participants had to meet specific criteria regarding both lifestyle factors and risk factors. Those factors included having low physical activity levels—meaning less than 60 minutes of moderate exercise per week—and not following the MIND diet, which is designed to support brain health. As for risk factors, participants needed to meet at least two of the following conditions:
A close family member (like a parent or sibling) had memory problems.
They had health risks like high blood pressure, high cholesterol or high blood sugar.
They identified as part of a racial or ethnic group that is often underrepresented in research, such as Native American, Black, Middle Eastern, or Hispanic or Latino.
They were in the older age range (70 to 79 years old) or were male, as men are often underrepresented in dementia prevention studies.
Both groups focused on improving brain health through physical activity, cognitive activity, healthy eating, social engagement and heart health monitoring. The difference between the two groups was in how the program was delivered. The first group was the structured group, and participants in this group received extra support from trained professionals and worked closely with peer teams of 10-15 people for motivation and accountability. Participants attended 38 team meetings over two years, and meetings were led by trained navigators and specialists. They also participated in the following:
Physical exercise: 30-35 minutes of moderate-to-intense aerobic activity four times a week, plus strength and flexibility exercises twice a week.
Cognitive exercise: Computer-based brain training program three times a week for 30 minutes, plus regular engagement in other intellectually challenging and social activities.
Nutrition: Adherence to the MIND diet, which emphasizes dark leafy greens, berries, nuts, whole grains, olive oil and fish, and limits sugar and unhealthy fats.
Health monitoring: Regular check-ins (every 6 months) on blood pressure, weight and lab results.
The second group was the self-guided group. This group was more independent but still had access to resources and support from peer teams and navigators from the Alzheimer's Association. Participants received publicly available resources about healthy lifestyle changes, such as tips on exercise, diet and brain health. They only attended six peer team meetings over two years, and had their health checked once a year during clinic visits, following standard health guidelines.
This study measured brain health and thinking abilities using a global cognitive score, which combined results from three key areas: executive function, which includes skills like planning, problem-solving, and multitasking; episodic memory, which focuses on remembering specific events or experiences; and processing speed, which measures how quickly the brain can handle information. To calculate the global score, participants completed a series of brain tests during clinic visits at the start of the study and every six months for two years.
What Did The Study Find?
Both groups in the U.S. POINTER study showed improvements in overall brain function over time as measured by their global cognitive scores. After adjusting for certain factors, the structured group improved slightly faster than the self-guided group, and this difference was statistically significant.
When focusing on the different cognitive areas the researchers measured, here is what they found:
Executive Function: In planning, problem-solving and multitasking, the structured group improved more than the self-guided group, and the difference was statistically significant.
Processing Speed: In gauging how long the brain took to process information, the structured group also showed slightly greater improvement—however, this difference was not statistically significant.
Episodic Memory: As for remembering specific events, both groups improved at about the same rate, with no meaningful difference between them.
The structured program seemed to have the biggest impact on participants who started the study with lower cognitive function. However, the structured program worked similarly well regardless of participants' sex, age or heart health at the start of the study. Additionally, the effects of the structured program were the same for people with or without the APOE ε4 gene, which research has linked to a higher risk of Alzheimer's disease.
In summary, the structured program provided the most benefit for executive function and was especially helpful for participants who started with lower cognitive abilities. Other factors like age, sex and genetic risk didn't seem to change how effective the program was.
This study has a few limitations to consider. First, the results might not apply to everyone because the study only took place at five sites, included participants specifically at higher risk for cognitive decline and required a significant two-year commitment from participants. Second, the study wasn't designed to measure whether the interventions could prevent cognitive impairment or dementia, so those outcomes remain unknown.
It's also worth noting that the self-guided group wasn't a true 'no-intervention' control group, as they still received some resources and support. Plus, participants knew which group they were in, which could have influenced their behavior or results. Additionally, it's unclear how long the benefits of the structured program will last, how easily it could be scaled up for larger populations or how meaningful the improvements are in the long term.
How Does This Apply to Real Life?
This study highlights the power of lifestyle changes when it comes to supporting brain health and reducing the risk of memory decline. It shows that combining regular exercise, a brain-healthy diet, mental stimulation and social engagement may make a real difference, especially for people at higher risk of dementia.
The structured program, which provided extra guidance and support, was particularly effective in improving skills like planning, problem-solving and multitasking. This observation suggests that having a clear plan and access to professional support may help people stick to healthy habits and see better results. But the self-guided group, which had more flexibility, showed improvements, proving that small, consistent changes in daily life can still benefit brain health.
This means that adopting healthier habits like staying active, following the MIND diet, engaging in mentally challenging activities, and staying socially connected can be a practical and accessible way to protect brain health. While the study focused on older adults at risk for dementia, the findings are a reminder that it's never too early or too late to start making positive changes.
Our Expert Take
A study recently published in JAMA provides valuable evidence that lifestyle changes can play a significant role in supporting brain health and reducing the risk of cognitive decline. In particular, these findings highlight the potential of combining regular exercise, a brain-healthy diet, mental stimulation and social engagement to improve cognitive health, especially for those at higher risk of dementia.
Both structured and self-guided programs led to improvements in overall brain function, with the structured program showing slightly greater benefits, particularly in areas like planning, problem-solving, and multitasking. Importantly, the study also demonstrated that even small, self-guided changes can make a meaningful difference, making these strategies accessible to a wide range of people.
Read the original article on EATINGWELL
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Cash pay is 'going to constitute a major part of the Wegovy business': Novo Nordisk CFO
Novo Nordisk (NVO) reported an earnings miss Wednesday, sending its stock down 4% in early trading, pressuring the stock further after a surprise management shake-up earlier in the year and sharply lowered guidance despite growing sales of its blockbuster GLP-1 drugs Ozempic and Wegovy. The stock is down more than 46% year to date as a result. CFO Karsten Munk Knudsen discussed some of the changes in recent weeks. He told Yahoo Finance that the leadership change — the ousting of CEO Lars Jørgensen and international head Mike Doustdar taking his place — was a surprise. "I was surprised about the changes of CEOs back in May," Knudsen said. "But ... looking at other companies ... when pressure is on, in terms of performance and competition, then it's not unusual that bosses and owners assess what's the right team to lead the company. In a macro setting I don't think its extraordinary, but in a Novo setting it was indeed surprising." The US market has also proven a challenge for Novo Nordisk, as it lost its lead despite a first-mover advantage to competitor Eli Lilly (LLY). Executives blame the compounding market, in which copycats are allowed under special circumstances, with telehealth platforms taking advantage of the loophole despite the FDA ending a shortage of GLP-1s that previously allowed copycats to freely sell on the market. Knudsen said the compounding market is about one-third of current GLP-1 prescriptions in the US market. On top of the competition and copycats, Novo Nordisk, like other big pharma names, has been targeted by the Trump administration to lower prices for consumers. It was one of 17 companies to receive a letter demanding lower costs for current and new products. "In reality, we're not that far apart in the sense that we also drive for affordable access in products that we supply. Our GLP-1 pricing is already rather low," Knudsen said, without revealing the actual numbers. Outgoing CEO Lars Jørgensen said on an earnings call Wednesday that its prices for Medicaid, for example, are already lower than in Europe. Those prices are not publicly available. The letter also asked the companies to price new drugs at the same low pricing found in other developed countries and to provide the lower cash prices more widely. Crunching cash numbers Some experts have expressed doubt about cash market success, however. Craig Garthwaite, a professor of strategy and healthcare at Northwestern University's Kellogg School of Management, posted on X in response to the Trump letters, questioning the strategy's viability. "How many customers do we believe have the ability (or willingness) to pay out of pocket for brand name drugs? A simple reading of the literature on increasing cost sharing suggests that people are not prepared to pay cash for these products — even if it is at the net and not the list price," Garthwaite said. But Knudsen noted that of its Wegovy patients in the US, 10% are paying cash through NovoCare, the direct-to-consumer channel, after it launched in March. "I am absolutely convinced that the cash channel is going to increase from here, and going to constitute a major part of the Wegovy business into the future," he said, adding that the overall cash market for GLP-1 in the US is already way above 10%. Knudsen referenced the compounding market, saying it provides insight into the potential, as those customers are cash-paying and represent one-third of the Wegovy market. But the cash price paid for copycats is significantly lower than the $499 per month available on NovoCare. Hims and Hers (HIMS), which Novo recently cut ties with over its refusal to stop selling compounded semaglutide, advertises prices as low as $199 per month for a 12-month plan of the copycat drug. Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, provider services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
Creatine for women: It carries benefits for every life stage
Think creatine is just for making gains at the gym? Think again. Emerging evidence suggests this powerhouse compound is also a major player in brain and muscle health. Once the go-to of bodybuilders and elite athletes, creatine has gone mainstream, gaining traction among everyday gym-goers and older adults looking to stay strong with age. Another growing area of interest? Creatine for women. Evidence suggests that women have significantly lower natural creatine stores than men — up to 80% less — and often consume less creatine in their diets. That gap could make creatine supplementation especially beneficial for women. Even more intriguing, a 2021 study published in Nutrients suggests creatine levels may rise and fall with hormone fluctuations. If you've ever felt wiped out right before your period? Low estrogen might be to blame — and creatine could be part of the fix. When estrogen dips (like it does premenstrually or during menopause), creatine metabolism changes, possibly affecting your energy and strength. Supplementing during these times may help your muscles stay fueled and your mood more steady. According to Jen Scheinman, MS, RD, menopause specialist and owner of Next Jen Health, 'Women can benefit from creatine at any age, but there are certain life stages where it may be especially helpful. During young adulthood, it can support strength, performance and recovery. In midlife, particularly during perimenopause and menopause, creatine may help counter muscle and bone loss, especially when paired with a protein-rich diet and resistance exercise. It may also support energy levels and improve mood and cognition. Even older women may see the benefit in muscle, brain and bone health.' Whether you're in your 20s, 30s, 40s, 50s or beyond, creatine could be a smart addition to your wellness routine. Here's what you should know about creatine for women — including which supplements to use — based on my expertise as a registered dietitian and insights from two women's health experts. Table of contents What is creatine? Health benefits of creatine for women How to take creatine Safety and side effects What women should look for in a creatine supplement Best creatine for women FAQs Meet our experts A note on supplements The products included on this list are dietary supplements. Statements about these products have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. Dietary supplements are not appropriate for everyone and may interact with other supplements or medications, so talk to your health care provider before adding a dietary supplement to your routine. What is creatine? Creatine is a naturally occurring compound that helps supply energy to your muscles, particularly during short bursts of intense activity. While it's most concentrated in skeletal muscle, smaller amounts are also found in the brain, heart and other tissues. According to a review in Nutrients, the body produces about 50% of the creatine you need each day; the rest you'll need to get from diet, through animal-based foods like red meat, poultry and fish. It's also a common ingredient in sports supplements, as it's been shown to be particularly beneficial for 'athletes who do a lot of sprints and jumps,' explains sports dietitian Jessica Garay, PhD, assistant professor of nutrition at Syracuse University and founder of Major League Wellness. While creatine is best known for its role in exercise performance, Garay notes that its benefits have been shown to extend outside the gym. 'We are now recognizing that the benefits of creatine supplementation are not limited to energy production within muscle. Studies have reported improvements in bone health, cognitive function and mental health,' she says. (back to top) Health benefits of creatine for women Boosts exercise performance and recovery When it comes to the role of creatine on exercise performance, the majority of research has been done either in men or competitive athletes. Still, while more studies are needed, creatine appears to have benefits for strength, power and athletic performance in healthy women, regardless of fitness level. According to a 2021 review in Nutrients, creatine has been shown to be particularly helpful for improving performance during high-intensity interval training and heavy lifting. Another review highlights research demonstrating a 20%–25% improvement in muscle strength in women following a 10-week regimen of combined creatine supplementation and strength training. Research also suggests that creatine may support post-workout recovery and help reduce the risk of injury. In a small randomized controlled trial published in 2025, adults (both men and women) who took 3 grams of creatine daily for 33 days experienced significantly faster recovery following a weight training session compared to those taking a placebo. Helps build and preserve lean muscle mass Thanks to its role in increasing energy in muscle cells and minimizing muscle breakdown, creatine has also been shown to be effective for building lean muscle mass — especially in premenopausal women. It may also play a key role in building and maintaining lean muscle mass during perimenopause, menopause and post-menopause. Declining levels of estrogen, testosterone and progesterone during these phases of life are a key contributing factor to age-related muscle loss. While more research is needed, creatine supplementation is thought to help counteract this effect, especially when paired with resistance training. Creatine supplementation may also help offset bone mass loss during and after menopause, though research is mixed. May help ease fatigue and bloating during your menstrual cycle One of the most exciting areas of research for women is the potential role creatine might play in managing symptoms throughout the menstrual cycle. 'Hormonal fluctuations throughout the cycle may impact how creatine is stored and used, and emerging evidence suggests it might help reduce bloating during the luteal phase (one week before your period) by shifting fluid into the cell,' says Scheinman. Feeling especially tired during certain phases of your cycle? Creatine might help with that too. 'Research suggests that supplementation may help alleviate fatigue-related symptoms during the early follicular and luteal phases, when dips in energy are common,' Scheinman says. However, Scheinman cautions that, while promising, there's still a lot we don't know about the role of creatine throughout the menstrual cycle. 'These benefits have been studied mostly in physically active women, so it's not yet clear if the same effects apply equally to sedentary women. While the research is promising, it's not yet robust enough to recommend cycle-specific dosing,' she says. May help alleviate symptoms of perimenopause and menopause 'During perimenopause (the transition to menopause) and menopause, women experience a decline in hormones that can lead to changes in body composition, fatigue, cognitive changes and mood fluctuations. While there is little research specifically looking at perimenopausal women, thought leaders suggest that creatine supplements may help preserve muscle mass and strength, support bone health and improve energy levels,' says Scheinman. A concern many women have during and after menopause is changes in body composition — especially belly fat. While there's no way to target fat in certain areas of the body, creatine may help with body composition changes by supporting the growth of lean muscle. 'Emerging research also suggests it may benefit brain function and help with the symptoms of forgetfulness and brain fog that so many perimenopausal women deal with,' says Scheinman, which could make getting to your morning workout or cooking healthy meals more manageable. May help improve memory and cognitive performance as you age Creatine doesn't just provide energy to your skeletal muscles — it also plays a role in energy production in your brain. While research in humans is limited, a 2023 review in Sports Medicine notes there's promising evidence that creatine may support memory, focus and mood, especially in older adults and during times of extreme stress. For women specifically, creatine supplementation may also help combat menopause-related fatigue. (back to top) How to take creatine Creatine typically comes in either powder or capsule form, though gummy options have also become increasingly popular. Unless recommended otherwise by a health care professional, it's best to follow directions listed on the supplement label. Powders can be mixed into virtually any hot or cold beverage or food. While some people prefer mixing them with water in a shaker bottle, others like adding them to their morning coffee or stirring them into a bowl of oatmeal. Creatine capsules tend to be on the larger side, so you'll want to have plenty of water nearby to help wash them down. Recommended dosage 'Historically, the protocol for creatine supplementation has always been a loading phase for 4 to 5 days of roughly 20 grams of creatine per day (0.3 grams creatine per kilogram (kg) body weight), then an ongoing maintenance dose of 5 grams per day (0.03 grams creatine per kg body weight),' says Garay. That said, some people prefer to forgo the loading phase and simply go straight to the recommended 5 grams per day. If you're interested in the cognitive benefits of creatine, research suggests a slightly higher dose of 5 to 10 grams daily might be helpful, says Garay. The best way to determine how much to take? Talk with a health care professional. Loading phase The loading phase is a strategy in which high doses of creatine are taken during the initial few days of use, before tapering down to the recommended 5 grams per day dose. 'The current thinking is that the loading phase definitely accelerates creatine stores in muscle, but it may not be necessary in the long-term because the lower dosage can still increase creatine levels over a 3–4 week timeframe,' says Garay. She also highlights that the loading phase could be helpful for those interested in creatine's benefits on brain health, though more research is needed about that. If you try the loading phase, Garay recommends splitting the recommended daily 15–20 gram dose into 5 gram increments to maximize absorption. So, take a 5-gram dose, three to four times a day for the initial loading period. When to take creatine According to Scheinman, there's no one best time to take creatine. 'For most people, the best time of day to take creatine is the time you are most likely to remember to take it. You want to take it consistently around the same time every day, whether that's morning, afternoon or evening. While there may be a slight benefit to taking it with food or around your workout, consistency matters most, especially for women looking to maintain steady levels over time,' she says. (back to top) Safety and side effects According to an article in Current Sports Medicine Reports, the official journal of the American College of Sports Medicine, creatine is one of the most well-researched supplements and is generally well-tolerated. The most common side effect is water retention, which typically resolves on its own after a few days. Other potential side effects include: nausea vomiting gastrointestinal discomfort constipation diarrhea reduced appetite While rare, serious side effects have been reported, and creatine may interact with certain medications. Before adding creatine to your supplement lineup, be sure to talk with your doctor or another health care professional first. As with any supplement, it's important to choose a high-quality option from a reputable brand. Because the Food and Drug Administration (FDA) doesn't regulate supplements in the same way as medications, the best way to ensure a supplement contains the ingredients and dosages that it claims to — and nothing else — is by looking for products that are third-party tested by organizations like NSF, Informed Choice or U.S. Pharmacopeia (USP). (back to top) What women should look for in a creatine supplement When shopping for creatine, the main factors to keep in mind are: creatine type dose flavored vs. unflavored 'Most of the research on creatine uses creatine monohydrate, so that's the form I recommend. Look for a supplement that provides 3 to 5 grams per serving and is third-party tested [for purity and potency],' says Scheinman. Garay echoes this sentiment, recommending particular caution with the rise in popularity of gummy products — many of which aren't third-party tested. '[Gummies] are an easy way to take creatine, but keep in mind that recent quality testing of some of these products has revealed that they may not actually contain any creatine!' Scheinman also adds that while some products are marketed specifically for women, 'The creatine itself isn't any different — these versions typically just add other ingredients. Unless you're specifically looking for those extras, there's no need to pay more for woman-focused branding.' If you do choose a product with added ingredients — like vitamins or minerals — just be sure you're not already getting those nutrients from other supplements. Some nutrients can be harmful in high doses when taken as supplements, so it's smart to avoid unnecessary overlap. Lastly, you'll want to take a look at the ingredient list and try to choose products with minimal artificial additives. If you prefer a flavored option, check the label for added sugars and the type of sweetener used. Regular sugar contributes to your total added sugar intake, while sugar alternatives like stevia or sucralose can have a distinct taste — or an aftertaste — that not everyone enjoys. (back to top) Best creatine for women While some products are marketed toward women, creatine supplements aren't gender-specific and can be taken by men or women. Here are three picks recommended by our experts, though you can find even more creatine supplements we like in our expert roundup of the best creatine supplements. (back to top) FAQs Will creatine make me bulk up? 'When someone starts a creatine supplementation protocol, especially if they follow a high-dose loading phase, there is an increased water retention in muscle to offset the higher creatine concentration. This is sometimes referred to as bulking up,' explains Garay. However, she notes that this effect is typically less pronounced in women, 'in part because females have a lower base level of creatine to begin with.' If you're worried about water retention, Garay recommends skipping the loading phase, as the smaller dose may help limit how much water retention occurs. Is creatine only for women who weight lift? No. All of our experts agreed that creatine offers benefits both in and out of the gym and may be particularly beneficial for certain groups. 'Vegetarian and vegan women may see even greater benefits, since their diets typically provide little to no creatine, leading to lower baseline levels in the body,' says Scheinman. How long does it take to see results? Garay explains that once it's absorbed, creatine is available for immediate use or stored for later. For athletic performance and strength, Garay says, 'We know it provides benefits after 10–12 weeks of consistent use. But some research studies have even shown benefits on exercise performance after only 5 days of supplementation compared to no creatine at all.' Can women in their 60s, 70s and beyond take creatine? 'Women of all ages can benefit from creatine, depending on their goals. It's one of the most well-studied supplements for performance and recovery in women across all age groups,' says Scheinman. For women in their later years, emerging evidence suggests that creatine may be helpful for improving cognitive function and may help preserve lean body mass, especially when paired with resistance training. (back to top) Meet our experts Jen Scheinman, MS, RD, CDN, menopause specialist and owner of Next Jen Health Jessica Garay, PhD, RDN, CSSD, FAND, assistant professor of nutrition at Syracuse University Falk College of Sport and founder of Major League Wellness (back to top) Our health content is for informational purposes only and is not intended as professional medical advice. Consult a medical professional on questions about your health.
Yahoo
3 hours ago
- Yahoo
Cell Line Development Market Outlook Report 2025-2034: PromoCell, Novartis, Genscript Biotech, Sartorius, and Thermo Fisher Scientific Dominate the Industry
Booming Biologics and Biosimilars Market Drives Global Cell Line Development Surge; CDMOs and Technological Advancements Key to Growth Cell Line Development Market Dublin, Aug. 06, 2025 (GLOBE NEWSWIRE) -- The "Cell Line Development Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034" has been added to offering. The Global Cell Line Development Market was valued at USD 7.5 billion in 2024 and is estimated to grow at a CAGR of 10.2% to reach USD 19.7 billion by 2034. Market expansion is being fueled by a growing focus on biologics and biosimilars, particularly as the pharmaceutical industry shifts toward personalized therapies and precision medicine. The surge in demand for monoclonal antibodies, vaccines, and recombinant proteins has placed strong emphasis on the development of highly stable and productive cell lines. The increase in chronic illnesses-such as autoimmune diseases, cancer, and infectious disorders-has led to the rising adoption of biologics, which depend heavily on well-characterized cell lines. This has also elevated the need for quality-controlled production systems. Contract development and manufacturing organizations (CDMOs) have contributed significantly to market momentum. Small and mid-sized biotech firms are increasingly outsourcing their cell line development to CDMOs to reduce overhead costs and accelerate timelines, benefiting from their technical expertise, scalable platforms, and regulatory compliance with agencies like the FDA. This trend allows companies to focus on core competencies such as research and innovation while leveraging CDMOs for end-to-end services including cell line screening, clone selection, process optimization, and GMP manufacturing. These partnerships also offer access to advanced technologies, streamlined workflows, and proven quality assurance frameworks, enabling faster entry into clinical trials and reducing risks associated with internal capacity limitations. The reagents and media segment generated USD 3.4 billion in 2024. This segment continues to dominate due to its central role in cell growth and maintenance across both R&D and production stages. With a notable increase in the use of mammalian cells for biologics manufacturing, the demand for high-efficiency reagents and cell culture media has surged. A growing preference for protein-free and serum-free media is helping the segment gain traction, offering improved scalability, reduced risk of contamination, and consistency in large-scale production environments. Such media types are essential for regulatory approval and efficiency in biologics manufacturing, which demands stringent process control. In terms of cell type, the mammalian cells segment generated the highest revenue in 2024, accounting for 71.4%. Their dominance is linked to their superior ability to express human-compatible therapeutic proteins with accurate post-translational modifications. Widely used cell lines such as CHO and HEK-293 are favored in biologics production due to their robust protein folding, glycosylation, and scalability. Technological progress in gene editing tools, such as CRISPR-Cas9, combined with automation and high-throughput systems, continues to enhance the speed and stability of mammalian cell line development, further reinforcing their leadership in the market. The United States Cell Line Development Market was valued at USD 2.6 billion in 2024, driven by a combination of advanced biopharma infrastructure, high rates of chronic disease, and strong adoption of cutting-edge biologic therapies. The country's well-established pharmaceutical ecosystem, which includes top-tier biotech firms and extensive R&D investment, plays a pivotal role in expanding the market. Research institutions and innovation hubs across the US are also accelerating technological advancements in gene editing and automated platforms, leading to faster and more efficient development cycles. Government and private sector funding are also propelling innovation, further supporting the country's leadership in the field. Key companies operating in the Global Cell Line Development Market include PromoCell, Novartis, Genscript Biotech, Sartorius, Thermo Fisher Scientific, ProBioGen, Cytiva (Danaher Corporation), ASIMOV, Advanced Instruments, Sigma Aldrich (Merck KGaA), Eurofins Scientific, WuXi AppTec, Aragen Life Sciences, Fyonibio, and Lonza Group. Top-tier players in the cell line development space are heavily investing in technological innovations like automated cell screening platforms, single-use bioreactors, and CRISPR-based genome editing. Many companies are forming strategic alliances with biotech firms and CDMOs to enhance service offerings and expand production capabilities. Acquisitions are also a popular move to integrate novel technologies or gain regional access. Firms are focusing on R&D to develop serum-free and chemically defined media, helping improve regulatory compliance and scalability. Comprehensive Market Analysis and Forecast Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape Competitive landscape with Porter's Five Forces and PESTEL analysis Market size, segmentation, and regional forecasts In-depth company profiles, business strategies, financial insights, and SWOT analysis Key Attributes Report Attribute Details No. of Pages 145 Forecast Period 2024-2034 Estimated Market Value (USD) in 2024 $7.5 Billion Forecasted Market Value (USD) by 2034 $19.7 Billion Compound Annual Growth Rate 10.2% Regions Covered Global Key Topics CoveredChapter 1 Methodology and ScopeChapter 2 Executive Summary2.1 Industry 360 synopsis2.2 Key market trends2.2.1 Regional2.2.2 Products & services2.2.3 Source2.2.4 Cell line2.2.5 Application2.2.6 End use2.3 CXO perspectives: Strategic imperatives2.3.1 Key decision points for industry executives2.3.2 Critical success factors for market players2.4 Future outlook and strategic recommendationsChapter 3 Industry Insights3.1 Industry ecosystem analysis3.1.1 Supplier landscape3.1.2 Value addition at each stage3.1.3 Factors affecting the value chain3.2 Industry impact forces3.2.1 Growth drivers3.2.1.1 Growing vaccine production worldwide3.2.1.2 Increasing prevalence of cancer across the globe3.2.1.3 Technological innovations in cell line development3.2.1.4 Growing biotechnology industry3.2.2 Industry pitfalls and challenges3.2.2.1 Complex regulatory landscape3.2.2.2 Challenges related to stem cell research3.2.3 Market opportunities3.2.3.1 Emerging applications in personalized medicine and regenerative therapies3.2.3.2 Adoption of artificial intelligence in cell line optimization3.3 Growth potential analysis3.4 Regulatory landscape3.4.1 North America3.4.2 Europe3.4.3 Asia Pacific3.4.4 Latin America3.4.5 Middle East and Africa3.5 Future market trends3.6 Emerging therapeutic applications of CHO cell lines3.7 Technology landscape3.7.1 Current technological trends3.7.2 Emerging technologies3.8 Porter's analysis3.9 PESTEL analysisChapter 4 Competitive Landscape, 20244.1 Introduction4.2 Company market share analysis4.3 Company matrix analysis4.4 Competitive analysis of major market players4.5 Competitive positioning matrix4.6 Key developments4.6.1 Merger and acquisition4.6.2 Partnership and collaboration4.6.3 New product launches4.6.4 Expansion plansChapter 5 Market Estimates and Forecast, By Products & Services, 2021 - 2034 ($ Mn)5.1 Key trends5.2 Reagents and media5.3 Equipment5.3.1 Incubator5.3.2 Centrifuges5.3.3 Bioreactors5.3.4 Storage equipment5.3.5 Microscopes5.3.6 Electroporators5.3.7 Fluorescence-activated cell sorting5.3.8 Other equipment5.4 Accessories and consumables5.5 ServicesChapter 6 Market Estimates and Forecast, By Source, 2021 - 2034 ($ Mn)6.1 Key trends6.2 Mammalian6.2.1 Chinese Hamster Ovary (CHO)6.2.2 Human Embryonic Kidney (HEK)6.2.3 Baby Hamster Kidney (BHK)6.2.4 Murine myeloma6.2.5 Other mammalian sources6.3 Non-mammalian6.3.1 Insects6.3.2 AmphibiansChapter 7 Market Estimates and Forecast, By Cell Line, 2021 - 2034 ($ Mn)7.1 Key trends7.2 Recombinant7.3 Hybridomas7.4 Continuous cell lines7.5 Primary cell linesChapter 8 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)8.1 Key trends8.2 Bioproduction8.3 Drug discovery8.4 Toxicity testing8.5 Tissue engineering8.6 ResearchChapter 9 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)9.1 Key trends9.2 Pharmaceutical and biotechnology companies9.3 Academic and research institutes9.4 Contract research organizations (CROs)Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)10.1 Key trends10.2 North America10.2.1 U.S.10.2.2 Canada10.3 Europe10.3.1 Germany10.3.2 UK10.3.3 France10.3.4 Italy10.3.5 Spain10.3.6 Netherlands10.4 Asia Pacific10.4.1 China10.4.2 Japan10.4.3 India10.4.4 Australia10.4.5 South Korea10.5 Latin America10.5.1 Brazil10.5.2 Mexico10.6 Middle East and Africa10.6.1 South Africa10.6.2 Saudi Arabia10.6.3 UAEChapter 11 Company Profiles11.1 Advanced Instruments11.2 Aragen Life Sciences11.3 ASIMOV11.4 Cytiva (Danaher Corporation)11.5 Eurofins Scientific11.6 Fyonibio11.7 Genscript Biotech11.8 Lonza Group11.9 Novartis11.10 ProBioGen11.11 PromoCell11.12 Sartorius11.13 Sigma Aldrich (Merck KGaA)11.14 Thermo Fisher Scientific11.15 WuXi AppTecFor more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Cell Line Development Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
